INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Fractyl Health, Inc. to Contact Law Firm
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Fractyl Health, Inc. to Contact Law Firm
PR Newswire
NEW YORK, Oct. 19, 2026
- Fractyl Health, Inc. (NASDAQ: GUTS) shareholders should email fletcher@fmoorelaw.com
NEW YORK, Oct. 19, 2026 /PRNewswire/ --
What is the Investigation About?
On January 29, 2026, before the market opened, Fractyl Health, Inc. announced six-month data from its REMAIN-1 Midpoint Cohort evaluating Revita for weight maintenance after discontinuation of GLP-1 therapy. Revita-treated patients experienced 4.5% weight regain, compared with 7.5% in the sham-treatment group. The Company also stated that the cohort was not designed to be sufficiently powered for efficacy analysis. During an investor call that same day, management disclosed that one study site had higher-than-expected weight regain across both treatment groups and materially contributed to the results.
Following this news, the price of Fractyl stock fell $1.245 per share, or 68.03%, to close at $0.585 per share on January 29, 2026.
After the market closed that day, Canaccord Genuity reported that management attributed the variability at one site to a less robust diet and lifestyle counseling program. Morgan Stanley also downgraded Fractyl and reduced its price target from $8.00 to $2.00. The next day, Fractyl stock fell another $0.125 per share, or 21.37%, to close at $0.46 per share on January 30, 2026.
If you own Fractyl Health, Inc. (NASDAQ: GUTS) securities, please contact Fletcher Moore at fletcher@fmoorelaw.com.
You may be able to seek monetary damages, corporate governance reforms, reimbursement to the company, and a court approved incentive award at no cost to you whatsoever. All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
MOORE LAW PLLC
30 Wall Street, 8th Floor
New York, NY 10005
fletcher@fmoorelaw.com
www.fmoorelaw.com
SOURCE Moore Law PLLC
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
3 of the Best Dividend Stocks to Own
The 10 Best Companies to Invest in Now
These Overvalued Stocks Have Plenty of Room to Fall
United States